BHVN DEADLINE NOTICE: ROSEN,A GLOBALLY RESPECTED LAW FIRM, Encourages Biohaven Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [4]. - The lawsuit claims that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed, resulting in investor damages [4].